The UK Charcot-Marie-Tooth Disease (CMT) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Charcot-Marie-Tooth disease (CMT) is a group of inherited conditions that damage the peripheral nerves. It’s also known as hereditary motor and sensory neuropathy (HMSN) or peroneal muscular atrophy (PMA). The peripheral nerves are found outside the main central nervous system (brain and spinal cord). They control the muscles and relay sensory information, such as the sense of touch, from the limbs to the brain.
People with CMT may have the symptoms like muscle weakness in their feet, ankles, legs, and hands, an awkward way of walking, highly arched or very flat feet, numbness in the feet, arms, and hands. The symptoms of CMT usually start to appear between the ages of 5 and 15, although they sometimes do not develop until well into middle age or later. CMT is a progressive condition. This means the symptoms slowly get worse, making everyday tasks increasingly difficult.
CMT is caused by an inherited fault in one of the many genes responsible for the development of the peripheral nerves. This fault means the nerves become damaged over time. A child with CMT may have inherited the genetic fault responsible for the condition from 1 or both of their parents. In the UK, it is estimated that approximately 25,000 people have CMT, making it the most common inherited neurological condition.
Market Growth Drivers
The increasing prevalence of Charcot Marie Tooth disease and the technological advancement in disease treatment will assist in encouraging the growth of the market. An increase in genetic disorders, due to a large number of genes causing this disease, an increase in innovations in this field, will also lead to a boost in the market growth.
The increased focus towards targeted therapies, along with the favorable government policies will additionally heighten numerous opportunities that will commence to the germination of the Charcot Marie Tooth disease market over the forecast period.
However, the high cost of treatment and the lack of awareness of Charcot Marie Tooth disease acts as a major restraint and as well as may hamper the market growth over the forecast period.